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of	 Cx62	 and	 3D	 structural	 models	 predicted	 its	 interference	 with	 gap	 junction	 and	13 




elevated	PKA-dependent	 signalling	 in	 a	 cyclic	 adenosine	monophosphate-independent	18 
manner,	and	was	not	observed	in	Cx57	deficient	mouse	platelets	(in	which	the	selectivity	19 











like	 structures	 (~2-3	nm)	 that	 facilitate	 contact-dependent	 inter-cellular	 trafficking	of	6 
small	 molecules	 (up	 to	 1	 kDa)	 between	 adjacent	 cells,	 enabling	 coordinated	 cellular	7 
responses.1,4.		8 
Gap	 Junctions	 and	 hemichannels	 have	 been	 studied	 in	 various	 cell	 types,	 where	 they	9 
mediate	 stable	 cellular	 interactions	 and	 through	 mediation	 of	 intercellular	 signalling	10 
coordinate	 synchronised	 cell	 function	within	 tissues.5	 The	 cardiovascular	 functions	 of	11 
connexins	 are	 well-characterised,	 from	 cardiac	 myocyte	 contraction6-8	 to	 control	 of	12 
vascular	 function.9-11	 Notably,	 connexins	 such	 as	 Cx37,	 Cx40	 and	Cx43,	 present	 in	 the	13 
vasculature,	have	been	reported	to	contribute	to	the	development	of	atherosclerosis12-14,	14 
a	process	in	which	circulating	inflammatory	cells	are	implicated.15-17	The	reported	roles	15 
of	 connexins	 in	 regulating	 the	 activities	 of	 immune	 cells	 including	 monocytes,	16 
macrophages,	 T	 cells,	 	 and	 dendritic	 cells,	 in	 addition	 to	 platelets,	 are	 therefore	17 
particularly	pertinent.18-21		18 
Platelets	are	regulators	of	hemostasis	and	aggregate	at	sites	of	vascular	damage	to	form	19 
thrombi	 that	 prevent	 excessive	 loss	 of	 blood.22,23	 Increasing	 evidence	 indicates	 the	20 




We	have	 reported	 the	presence	of	 Cx37	 and	Cx40	 in	platelets	 and	 through	 the	use	 of	1 
selective	mimetic	peptides	and	transgenic	gene-deficient	mice,	demonstrated	that	both	2 
hemichannels	 and	 gap	 junctions	 are	 required	 for	 platelet	 activation	 and	 thrombus	3 
formation.26,27	In	addition	to	Cx37	and	Cx40,	we	observed	notable	levels	of	Cx62	mRNA	4 
transcripts	 in	 megakaryocytes	 and	 circulating	 cells	 such	 as	 B-cells,	 T-cells	 and	5 
monocytes.26	 Very	 little	 is	 known	 regarding	 the	 properties,	 function	 and	 tissue	6 









functional	 assays	 such	 as	 aggregation,	 dense	 granule	 secretion,	 fibrinogen	 binding,	 P-16 
selectin	 exposure,	 calcium	 mobilization,	 clot	 retraction,	 platelet	 spreading,	 thrombus	17 
formation,	 and	 tail	 bleeding	 was	 performed	 as	 described	 previously.26,27,30-32	Detailed	18 
descriptions	of	reagents	and	these	methods	are	provided	in	Supplemental	Methods.	19 
Mice	20 
Gja10em2(IMPC)Mbp	 mice	 were	 produced	 by	 insertion	 of	 an	 indel-causing	 frameshift	21 
mutation	by	the	International	Mouse	Phenotyping	Consortium	(IMPC)	at	the	University	22 









in	 tail	 bleeding	 assay).	 Data	 represent	 mean ± SD	 and	 P < 0.05	 was	 considered	 to	 be	8 







were	confirmed	not	 to	express	detectable	 levels	of	Cx62.	 Immunofluorescence	 studies	16 
performed	on	resting	permeabilized	human	platelets	revealed	Cx62	(stained	red)	to	be	17 
present	 in	 a	punctate	 arrangement	 inside	platelets	 (stained	green	 for	GPIb)	 and	were	18 
redistributed	towards	the	periphery	of	the	cells	upon	activation	with	the	TxA2	mimetic	19 
peptide	 U46619	 (used	 at	 a	 concentration	 at	which	 platelet	 shape-change	 is	minimal)	20 
(Figure	1B-C).		21 
We	 also	 utilized	 super-resolution	 STORM	 microscopy	 to	 determine	 the	 subcellular	22 





of	 Cx62	 primary	 antibody)	 was	 performed	 to	 exclude	 the	 possibility	 of	 non-specific	3 
staining	(Supplemental	 figure	1A).	To	 further	confirm	the	 translocation	of	Cx62	to	 the	4 
plasma	membrane	 upon	 platelet	 activation,	 co-localization	 of	 integrin	 β3	 subunit	 and	5 






20%	 of	 the	 Cx62	 population	 co-localized	 with	 integrin	 β3,	 which	 increased	 to	12 
approximately	85%	upon	platelet	activation	(5	minutes)	(Figure	1E).		13 
To	 further	explore	 the	subcellular-location	of	Cx62	 in	platelets,	we	performed	a	 linear	14 
sucrose	 density	 gradient	 centrifugation	 on	 platelet	 homogenates,	 following	 nitrogen	15 
cavitation.	Cx62	was	highly	concentrated	 in	 the	 low-density	 fractions	(1	and	2)	with	a	16 
distribution	profile	similar	to	that	of	calreticulin	[a	marker	of	the	dense	tubular	system	17 
(DTS)]	and	β3	integrin	but	was	absent	from	higher	density	fractions	(9	and	10),	where	a-18 




To	 assist	 in	 the	 design	 and	 analysis	 of	 an	 inhibitory	mimetic	 peptide	 that	 specifically	23 
targets	Cx62(57),	the	monomeric	and	oligomeric	structures	of	Cx62	were	predicted.	The	24 
 7 
predicted	 tertiary	 structure	 of	 Cx62	 from	 the	 IntFOLD	 server35	 reveals	 a	 protomer	1 
(monomer	subunit)	consisting	of	four	transmembrane	helices,	two	extracellular	loops,	a	2 
small	 bended	 N-terminal	 helix,	 and	 a	 long	 disordered	 cytoplasmic	 C-terminus	 loop	3 
(Figure	2A-B).	The	ModFOLD636	global	3D	model	quality	score	for	the	full-length	protein	4 
was	calculated	as	0.43	(p	<	0.01;	less	than	a	1	in	100	chance	of	being	incorrect),	which	5 
increased	to	0.57	(p<0.001;	 less	 than	a	1	 in	1000	chance	of	being	 incorrect)	when	the	6 
long-disordered	 C-terminal	 loop	 was	 excluded.	 The	 calculated	 local	 (or	 per-residue)	7 
errors	indicate	that	the	ordered	regions	of	the	Cx62	structure	were	modelled	with	high	8 
confidence	(Figure	2A).	The	tertiary	structure	model	of	Cx62	was	subsequently	used	as	a	9 
target	 for	 in	 silico	 docking	 with	 the	 designed	 mimetic	 peptide,	 and	 for	 quaternary	10 
structure	assembly	of	the	docked	hemichannel	complex	(Figure	2C-E).	11 
Design	of	the	Cx62	Mimetic	Peptide	(62Gap27)	and	Protein-Ligand	Docking	Studies	12 




that	were	bound	in	approximately	the	same	location	at	 the	end	of	 the	second	external	17 
loop	(Figure	2B)	(Supplemental	figure	1D).	18 
Cx62	Forms	Hemichannels	and	Gap	Junctions	in	Platelets	19 
The	 exact	 mode	 of	 action	 by	 which	 different	 Gap27	 peptides	 function	 is	 not	 clearly	20 
understood.	It	is	believed	that	they	induce	a	conformational	change	in	the	hemichannel,	21 
that	 prevents	 them	 from	 docking	 to	 form	 a	 gap	 junction	 and	 thus	 modulate	 the	22 
permeability	of	the	pore.21,26,37,38	To	investigate	this,	we	performed	flow	cytometry	using	23 





platelets	 with	 62Gap27	 (100	 μg/ml)	 prevented	 this	 loss	 of	 fluorescence.	 Since	 flow	4 
cytometry-based	analyses	involve	the	gating	of	individual	platelets,	this	indicates	a	role	5 
for	Cx62	hemichannels	in	regulating	platelet	permeability.	Given	the	strong	reduction	in	6 




(a	marker	of	α-granule	 secretion)	on	 the	platelet	 surface,	 in	 comparison	 to	 scrambled	11 
peptide	 treatment	 (Supplemental	 figure	 1C).	 This	 suggests	 that	 the	 effects	 of	 62Gap27	12 
observed	 on	 the	 permeability	 of	 hemichannels	 were	 not	 due	 to	 a	 reduction	 in	 the	13 
activation	state	of	platelets	under	these	experimental	conditions.	14 
To	 evaluate	 the	 ability	 of	 62Gap27	 to	 modulate	 gap	 junction-mediated	 intercellular	15 




platelet	 aggregates	 was	 halved	 in	 comparison	 to	 scrambled	 peptide-treated	 samples	20 
(17%)	 (Figure	 2H-I).	 These	 findings	 demonstrate	 gap	 junction-mediated	 intercellular	21 
communication	between	platelets	and	the	inhibitory	effect	of	62Gap27	on	this.	22 
The	model	of	the	Cx62	hemichannel	complex	(Figure	2C-D)	revealed	the	two	interacting	23 




Protomer-inhibitor	(Cx62-62Gap27)	 interface	residues	were	not	 found	to	coincide	with	3 
the	 interface	 residues	of	 the	12-mer	 (docked-hemichannel).	Additionally,	 there	are	no	4 
SwissDock	poses	within	the	most	common	62Gap27	inhibitor	interaction	location	(Figure	5 












washed	 platelets	 stimulated	 with	 a	 range	 of	 platelet	 activators	 that	 target	 different	18 
receptors.	The	concentrations	of	platelet	agonists	used	were	optimized	for	each	donor	to	19 
attain	50%	maximal	aggregation	(EC50)	following	3	minutes	of	stimulation.	Pre-treatment	20 






observed	 against	 CRP-XL	 and	 thrombin-stimulated	 aggregation	 respectively.	 62Gap27	2 






binding	 was	 reduced	 by	 55%	 and	 65%	 respectively,	 following	 62Gap27	 (100	 μg/ml)	9 
treatment	(Figure	3C).	The	scrambled	peptide	was	without	effect	(Supplemental	figure	10 
2D).	 Since	 fibrinogen	 binding	 was	 measured	 on	 gated	 single	 platelets,	 this	 provides	11 





platelet	 connexins	 such	 as	 Cx37	 and	 Cx40	 (Supplemental	 figure	 3A-B).	 Similarly,	 the	17 
deletion	of	Cx37	and	Cx40	did	not	affect	the	expression	of	Cx57	(Supplemental	figure	3C-18 
D).	The	expression	of	GPVI,	 integrin	α2β1,	 integrin	αIIbβ3	and	GPIb	on	 the	 surface	of	19 
Cx57+/+	and	Cx57-/-	platelets	was	not	significantly	different	(Supplemental	figure	3E-H).		20 
In	comparison	with	scrambled	peptide,	 treatment	with	62Gap27	(100	µg/ml)	 inhibited	21 
CRP-XL-mediated	fibrinogen	binding	in	Cx57+/+	platelets	(in	PRP)	but	was	without	effect	22 
on	Cx57-/-	platelets	(Figure	3D),	confirming	the	specificity	of	62Gap27	for	Cx57,	which	in	23 
turn	 signifies	 its	 selectivity	 for	 Cx62	 in	 humans.	 Additionally,	 37,43Gap27	 and	 40Gap27	24 
 11 
treatment	 (mimetic	 peptides	 for	 Cx37	 and	 Cx40,	 respectively)	 significantly	 inhibited	1 
fibrinogen	binding	in	both	Cx57+/+	and	Cx57−/−	platelets	(Figure	3D).	Consistent	with	this,	2 
62Gap27	 also	 inhibited	 CRP-XL-stimulated	 fibrinogen	 binding	 in	 Cx37−/−	 and	 Cx40−/−	3 
platelets	to	a	similar	extent	as	in	littermate	Cx37+/+	and	Cx40+/+	platelets	(Supplemental	4 
Figure	 4A-B).	 This	 suggests	 that	 Cx37,	 Cx40	 and	 Cx57	 hemichannels	 can	 function	5 
independently	of	each	other	in	platelets	and	the	deletion	of	one	connexin	does	not	affect	6 
the	 functions	 of	 other	 platelet	 connexins.	 Furthermore,	 a	 significant	 reduction	 in	7 
fibrinogen	binding	was	observed	in	CRP-XL-stimulated	Cx57-/-	platelets,	in	comparison	to	8 





luciferin-luciferase	 luminescence	 assay,	 respectively.	 Incubation	 of	 platelets	 (in	 PRP)	14 
with	 62Gap27	 attenuated	 (in	 comparison	 to	 scrambled	 peptide)	 P-selectin	 exposure,	15 
reaching	 60%	 inhibition	 (at	 100	 μg/ml	 62Gap27)	 upon	 stimulation	 with	 CRP-XL	 or	16 
thrombin	(Figure	3F).	Scrambled	peptide	(100	μg/ml)	was	without	effect	(Supplemental	17 
Figure	 4C).	 CRP-XL	 or	 thrombin-stimulated	 ATP	 release	 was	 also	 attenuated	 by	18 
approximately	65%	and	50%	respectively	upon	treatment	with	62Gap27	(100	μg/ml),	in	19 
comparison	to	the	scrambled	peptide	(Figure	3G).		20 
Activated	 platelets	 synthesize	 TxA2	 to	 provide	 positive	 feedback,	 enabling	 the	21 
recruitment	of	more	platelets	 to	 the	hemostatic	plug.39	Treatment	of	washed	platelets	22 




Binding	 of	 fibrinogen	 to	 integrin	 αIIbβ3	 initiates	 integrin	 clustering	 and	 outside-in	2 
signaling	 that	 reinforces	 platelet	 activation	 and	 ensures	 the	 stability	 of	 thrombus.40	3 
Platelet	spreading	and	clot-retraction	are	direct	outcomes	of	outside-in	signaling.41	The	4 






platelet	 signaling	 that	 are	 associated	 with	 Cx62	 function	 and	 can	 modulate	 integrin	11 
affinity	 and	 fibrinogen	 binding.	 Consistent	 with	 this,	 fibrin	 clot	 retraction	 was	 also	12 




the	 effects	 of	 62Gap27	 on	 thrombus	 formation	 in	 vitro	using	 fluorescence	microscopy.	17 
DiOC6-labelled	 whole	 human	 blood,	 treated	 with	 scrambled	 peptide	 or	 62Gap27	18 
(100μg/ml),	 was	 perfused	 through	 collagen-coated	 microfluidic	 flow	 channels	 for	 10	19 
minutes	 at	 a	 shear	 rate	 of	 500	 s-1	 (20	 dyn/cm2).	 The	 mean	 fluorescence	 intensity	 of	20 
thrombi	 in	 62Gap27-treated	 whole-blood	 was	 reduced	 by	 70%,	 in	 comparison	 with	21 
scrambled	peptide	 (Figure	4C).	Furthermore,	 the	extent	of	 thrombus	surface	coverage	22 
was	also	attenuated	 in	62Gap27-treated	samples,	consistent	with	 impaired	adhesion	of	23 
platelets	(Supplemental	Figure	4D).	24 
 13 
The	 acute	 effects	 of	 62Gap27	 (100	 μg/ml)	 on	 thrombosis	 was	 investigated	 in	 mice	1 
following	 laser-induced	 injury	 of	 cremaster	 muscle	 arterioles	 and	 observed	 using	2 




The	contribution	of	Cx57(62)	 to	haemostasis	was	assessed	by	measuring	 tail-bleeding	7 






Given	 the	 effects	 of	 62Gap27	 on	 CRP-XL-mediated	 platelet	 responses	 and	 thrombus	14 
formation	 in	 vitro	 and	 in	 vivo,	 we	 investigated	 the	 effects	 of	 62Gap27	 on	 signal	15 
transduction	 stimulated	 by	 the	 GPVI	 receptor.	 Pre-treatment	 of	 platelets	 (non-16 
aggregation	conditions)	with	62Gap27	(50	and	100	µg/mL)	for	5	minutes	reduced	CRP-17 
XL-stimulated	 total	protein	 tyrosine	phosphorylation	by	approximately	25%	and	30%	18 
respectively,	in	comparison	with	scrambled	peptide	(Figure	5A).	Consistent	with	this,	100	19 
µg/ml	 of	 62Gap27	 inhibited	 the	 tyrosine	 phosphorylation	 of	 Syk	 (Tyr525/526)	 by	~30%	20 
(Figure	5B).	This	indicated	that	62Gap27	inhibits	the	early	stages	of	the	GPVI	signaling.	21 














attenuated	 by	 45%	 (Figure	 5F),	 following	 incubation	 with	 62Gap27	 (100	 μg/ml).	12 




In	 comparison	with	 scrambled	 peptide,	 62Gap27	 also	 inhibited	 thrombin-evoked	 total	17 
protein	 tyrosine	 phosphorylation,	 calcium	 mobilization,	 the	 release	 of	 calcium	 from	18 




platelets	 showed	 reduced	 CRP-XL-evoked	 total	 tyrosine	 phosphorylation	 and	23 
phosphorylation	of	Syk	(Tyr525/526),	LAT	(Tyr200),	PLCγ2	(Tyr1217)	and	PKC	substrates	in	24 
 15 







cells.42,43	 PGI2	 binds	 to	 IP	 receptor	 and	 stimulates	 the	 production	 of	 cyclic	 adenosine	8 
monophosphate	 (cAMP),	 while	 NO	 stimulates	 the	 production	 of	 cyclic	 guanosine	9 
monophosphate	 (cGMP)	 which	 activate	 protein	 kinase	 A	 (PKA)	 and	 protein	 kinase	 G	10 
(PKG),	respectively,	and	inhibit	platelet	activation	through	phosphorylation	of	multiple	11 
substrates.44,45		12 
We	 therefore	 explored	 the	 effect	 of	 62Gap27	 on	 PKA	 and	 PKG-dependent	 signaling	 in	13 
platelets	 by	 measuring	 the	 extent	 of	 VASP	 (Vasodilator-stimulated	 phosphoprotein)	14 




was	 also	 elevated	 in	 CRP-XL-stimulated	 platelets	 that	 were	 treated	 with	 62Gap27	 in	19 



















platelets,	 62Gap27-treated	 Cx57+/+	 mouse	 platelets	 exhibited	 enhanced	 VASP	 S157	14 








(10	 µM),	 PI3-Kinase	 inhibitor	 LY29400	 (100	 µM)	 or	 AKT	 inhibitor	 IV	 (5	 µM)	23 
(Supplemental	 figure	 6D-F).	 Together,	 these	 observations	 provide	 insight	 into	 the	24 
 17 




CD72,	 plexin-B1	 and	 CD40L)	 in	 contact-dependent	 signaling	 that	 is	 required	 for	 the	5 
formation	 of	 a	 stable	 thrombus.48,49	 The	 contributions	 of	 gap	 junction-mediated	6 
intercellular	 communication	 to	 platelet	 function	 and	 thrombus	 growth	 represents	 a	7 






upon	 platelet	 activation	 remains	 to	 be	 established.	 In	 other	 cell	 types,	 connexins	14 
translocate	 to	 the	 plasma	 membrane	 through	 the	 classical	 secretory	 pathway.50-54	 In	15 
platelets,	Cx62	is	distributed	similarly	to	calreticulin,	present	within	the	DTS	(remnants	16 
of	megakaryocyte	smooth	endoplasmic	reticulum)	but	not	 in	subcellular	 fractions	 that	17 




become	 mobilized	 in	 activated	 platelets,	 and	 therefore	 may	 share	 mechanisms	 of	22 
trafficking	towards	the	cell	surface	with	Cx62.56	23 
 18 












FRAP	experiments	confirmed	the	 formation	of	Cx62-containing	gap	 junctions	between	13 
adjacent	platelets.	Thrombus	stability	was	suppressed	both	in	vitro	and	in	vivo	following	14 
treatment	 with	 62Gap27,	 indicating	 the	 vital	 role	 of	 gap	 junction	 intercellular	15 
communication	in	the	reinforcement	of	thrombi.	It	is	plausible	that	such	robust	effects	of	16 
62Gap27	 on	 thrombosis	 in	 vivo	 are	 partly	 due	 to	 its	 effects	 on	 other	 circulating	 or	17 
endothelial	cells.	Further	work	to	explore	this	will	require	transgenic	mice	with	platelet-18 
specific	deletion	of	Cx57.	19 
Studies	 in	Cx57-deficient	mouse	platelets	 identified	 that	Cx57(62)	positively	 regulates	20 
platelet	function,	hemostasis	and	thrombus	formation.	These	functions	are	shared	with		21 
Cx37	and	Cx40,	the	other	principal	platelet	connexins.21,26,27,58		We	also	observed	negative	22 





to	 interact	 with	 the	 calcium	 channel	 P2X1.60	 It	 is	 therefore	 possible	 that	 Cx62	 may	3 
associate	with	a	platelet	calcium	channel	to	influence	calcium	mobilization.	4 
PKA	activation	plays	an	essential	role	in	the	regulation	of	platelet	function	by	controlling	5 
several	 aspects	 of	 activation	 including	 integrin	 αIIbβ3	 affinity,	 inositol	 1,4,5-6 
trisphosphate	 (IP3)	 receptor	 function	 and	 shape	 change	 via	 actin	 polymerisation.61,62	7 
While	cAMP	is	a	key	activator	of	PKA	in	platelets,	studies	have	also	reported	that	PKA	8 
activity	can	be	stimulated	by	collagen	or	thrombin	in	a	cAMP-independent	manner,	and	9 
in	 other	 cells,	 cAMP-independent	 PKA	 activation	 has	 been	 attributed	 to	 the	 effects	 of	10 
sphingosine	and	free	radicals.47,63-65	We	provide	compelling	evidence	that	the	inhibitory	11 
effects	 of	 62Gap27	 on	 platelets	 are	 mediated	 through	 increased	 PKA	 activity,	12 






(AKAPs)	 that	may	modulate	 PKA	 activity	 in	 the	 vicinity	 of	 the	 connexin.	 	 The	 lack	 of	19 
increased	VASP	phosphorylation	 in	Cx57-deficient	platelets	 in	 the	 absence	of	 62Gap27	20 
suggests	that	Cx	binding	of	PKA	may	result	in	its	activation,	while	non-Cx57-bound	PKA	21 
is	inactive.				22 







the	 absence	 of	 Cx57,	 which	 in	 itself	 does	 not	 alter	 PKA-dependent	 signalling	 in	5 
unstimulated	platelets,	results	in	diminished	levels	of	platelet	activation.		This	supports	a	6 
role	for	Cx57	channel	activity	 in	the	function	of	platelets.	 	 It	remains	to	be	established	7 
whether	the	inhibitory	effects	of	62Gap27	are	solely	mediated	through	stimulation	of	PKA	8 
signalling	 (which	 is	 dependent	 on	 the	 presence	 of	 the	 connexin)	 or	 also	 through	9 
modulation	 of	 channel	 function.	 It	 is	 pertinent	 that	 several	 studies	 indicate	 the	10 
involvement	of	PKA	and	PKG	in	regulating	the	phosphorylation	of	Cx32,	Cx35/36,	Cx40,	11 







Gap27	 peptide	 docking	 experiments	 are	 suggestive	 of	 regulation	 of	 gating	 by	19 
conformational	changes,	although,	as	discussed,	modulation	of	PKA-dependent	signaling	20 
may	 also	 be	 important.	 Non-peptide	 based	 selective	 inhibitors	 would	 need	 to	 be	21 
developed	 that	 potentially	 mimic	 peptide	 binding	 and/or	 associated	 conformational	22 
changes	in	order	to	develop	this	further.		A	suggested	starting	point	for	such	work	would	23 
 21 
be	 the	 development	 of	 biologics	 that	 target	 the	 proposed	 62Gap27	 binding	 sequences	1 
predicted	in	Cx62.	2 
In	 summary,	 we	 have	 identified	 key	 functions	 for	 the	 orphan	 connexin,	 Cx62(57)	 in	3 
platelets	 in	 the	 regulation	 of	 hemostasis	 and	 thrombosis.	 We	 have	 revealed	 a	 new	4 
signaling	mechanism	through	which	Cx62(57)	and	its	inhibitor	modulate	cellular	function	5 
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was	 examined	 by	 immunoblot	 analysis	 of	 whole-cell	 lysates	 from	 human	 and	mouse	3 
whole	 platelets,	MegO1	 and	HeLa	 cells	 using	 a	 rabbit	 polyclonal	 anti-GJA10	 antibody.	4 







permeabilized	 human	 platelets	 were	 stained	 using	 anti-GJA10	 and	 anti-integrin	 β3	12 
primary	antibodies	and	visualized	using	Alexa-647	and	Alexa-555-conjugated	secondary	13 








intercellular	 communication.	 (A)Predicted	 3D	model	 of	 the	 Cx62	 tertiary	 structure.	22 
The	ribbon	view	of	the	structure	is	colored	using	the	temperature	coloring	scheme,	where	23 
blue	indicates	ordered	regions	with	low	predicted	per-residue	errors	and	red	indicates	24 
high	 per-residue	 errors	 and	 more	 flexibility.	 (B)	 Schematic	 representation	 of	 the	25 
designed	62Gap27	sequence	on	Cx62.	The	topological	diagram	of	the	Cx62	protomer,	the	26 
predicted	binding	site	(BS)	is	highlighted	in	orange.	(NT:	NH2-terminus,	CL:	Cytoplasmic	27 
loop,	 CT:	 COOH-terminus,	 T:	 Transmembrane,	 E:	 Extracellular)	 (C)	 Surface	28 
representation	of	Cx62	hemichannels	being	targeted	by	62Gap27	showing	the	pore	cross-29 
section	and	side	views	respectively.	 (D)	 Inter-protomer	 interactions.	The	hemichannel	30 
formed	by	six	protomers	of	Cx62	 is	 shown	 in	grey	ribbon	view,	 the	side-chains	 in	 the	31 
zoomed	views	are	shown	as	sticks	with	brown	and	yellow	colors	to	differentiate	between	32 
the	 residues	 of	 interacting	 protomer	 pairs.	 (E)	 Modeled	 intercellular	 interactions	33 
between	docked	 hemichannels.	 In	 the	 left-hand	panel,	 a	 Cx62	 gap	 junction	 channel	 is	34 
shown.	The	region	enclosed	by	dashed	lines	is	sectioned	perpendicular	to	the	pore	axis	35 
and	 is	 viewed	 from	 the	 pore	 axis	 (right-hand	 panel).	 The	 interactions	 between	 the	 2	36 
docked	 hemichannels	 (the	 first	 external	 loop	 (E1)	 and	 the	 second	 external	 loop	 (E2)	37 





calcein	 from	 human	 platelets	 was	 measured	 using	 flow	 cytometric	 analysis.	 Calcein	1 
loaded	 platelets	 incubated	 with	 62Gap27	 or	 scrambled	 peptide	 (100	 μg/ml)	 were	2 
stimulated	with	thrombin	(0.1	U/ml).	Representative	histograms	of	calcein	fluorescence	3 
for	unstimulated	(green),	and	thrombin-stimulated	platelets	in	the	presence	of	scrambled	4 
(blue)	 or	 62Gap27	 (100µg/ml)	 (orange)	 (n=4).	 (G)	 Calcein	 efflux	 following	 thrombin	5 
stimulation	for	varying	time	periods	was	measured	by	the	rate	of	fluorescence	reduction	6 
in	 platelets.	 Median	 fluorescence	 intensity	 for	 unstimulated	 and	 stimulated	 samples	7 
treated	with	scrambled	or	62Gap27	was	analyzed	(n=4).	(H)	Calcein	loaded	platelets	were	8 
treated	with	scrambled	or	62Gap27	(100µg/ml)	for	5	minutes	before	their	stimulation	on	9 
fibrinogen	 and	 collagen-coated	 coverslips	 and	 FRAP	 analysis	 was	 performed.	10 
Representative	images	represent	fluorescence	recovery	(Pre-bleach,	At-bleach	and	Post-11 
bleach)	 in	 samples	 treated	 with	 scrambled	 or	 62Gap27.	 Data	 represent	 Mean	 ±	 SEM,	12 
****P˂0.0001	 was	 calculated	 by	 two-way	 ANOVA.	 (I)	 Quantified	 data	 shows	 mean	13 
fluorescence	 recovery	 intensity	 of	 scrambled	 and	 62Gap27	 treated	 samples	 and	14 
normalized	 to	 the	 level	of	 fluorescence	at	bleach	point	 (shown	 in	red	circles;	panel	G)	15 
(n=5).		16 
	17 




optical	 light	 transmission	 aggregometry	 for	 180	 seconds.	 Representative	 aggregation	22 









stimulation	 with	 CRP-XL	 (0.25	 μg/ml)	 or	 thrombin	 (0.05	 U/ml).	 (G)	 Changes	 in	 ATP	32 
release	were	monitored	for	5	minutes	in	washed	platelets	(4	x	108	cells/ml)	incubated	33 




U/mL).	 Data	 represent	 mean	 ±	 SEM	 (n≥3),	 *P˂0.05,	 **P˂0.01	 and	 ***P˂0.001	 was	38 
calculated	by	one-way	ANOVA.	†P˂0.05	was	calculated	by	the	Student	t-test.	39 
 28 
Figure	 4.	 62Gap27	 inhibits	 integrin	 αIIbβ3-mediated	 signaling,	 thrombosis	 and	
hemostasis.	(A)	Human	washed	platelets	(2×107	cells/mL	)	incubated	for	5	minutes	with	
62Gap27	 (50	 and	 100	 μg/ml)	 or	 scrambled	 peptide	 (S;	 100	 μg/ml)	 were	 exposed	 to	
fibrinogen	 (100	 μg/mL)	 coated	 coverslips.	 Representative	 images	 of	 spreading	 and	
adhesion	 of	 platelets	 after	 45	 minutes	 and	 cumulative	 data	 of	 platelets	 adhered	 to	
fibrinogen	in	each	sample	are	shown.	Spreading	platelets	were	categorized	into	3	groups	
(adhered	but	not	spread;	 filopodia:	platelets	 in	 the	process	of	extending	 filopodia;	and	







at	 the	 end	 of	 the	 assay	 (10	 mins)	 and	 quantified	 data	 represent	 mean	 thrombus	
fluorescence	 intensity.	 (D)	 In	 vivo	 thrombosis	 was	 assayed	 by	 intravital	 microscopy	
following	 the	 laser-induced	 injury.	 62Gap27	 or	 scrambled	 peptide	 (100	 μg/ml)	 was	
administered	intravenously	to	mice,	and	platelets	were	fluorescently	labeled	with	Alexa-
647–conjugated	 anti-GPIb	 antibody.	 After	 laser	 injury,	 platelet	 accumulation	 and	
thrombus	formation	were	assessed.	Representative	 images	at	different	time-points	are	
shown	 and	 data	 are	 expressed	 as	 median	 fluorescence	 intensity.	 (E)	 The	 mean	 of	













μg/ml)	 or	 scrambled	 peptide	 (S,	 100	 μg/ml)	 pre-treated	 human	 washed	 platelets	
(4×108	cells/mL)	 were	 stimulated	 for	 90	 seconds	 with	 CRP-XL	 (1	 μg/ml)	 under	 non-









peptide	 (S;	 100	μg/ml)	 for	 5	minutes	 prior	 to	 stimulation	with	CRP-XL	 (0.25	μg/mL).	
Spectrofluorimetry	was	used	to	measure	the	release	of	calcium	from	intracellular	stores.	
Representative	traces	of	calcium	mobilization	over	a	period	of	5 minutes	and	quantified	









A)	 total	 tyrosine	 phosphorylation	 and	 B)	 Syk	 phosphorylation	 (Tyr525/526),	 C)	 LAT	









were	 tested	 for	 VASP	 S157	 phosphorylation	 (a	 marker	 of	 PKA	 activity).	 VASP	 S157	
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Cx62 antibody was obtained from Sigma-Aldrich. The anti-phosphotyrosine antibody 4G10 was 
obtained from Millipore, USA and the phospho-specific antibodies - PLCγ2 (Y759), AKT (S473), 
myosin light chain (S19) and vasodilator-stimulated phosphoprotein (VASP) phospho-Ser157 and 
Ser239 were obtained from cell signaling technologies, USA. Syk (pY525/526) and LAT (Y200) 
antibodies were from Abcam. Anti-Phospho–PKC substrate antibody was purchased from New 
England BioLabs, USA. Mouse anti-human 14-3-3ζ (Santa Cruz Biotechnology, USA) was used to 
detect 14-3-3ζ to ensure equivalent levels of protein loading in immunoblots. The secondary 
antibodies used for immunoblotting; Cy5 goat anti-rabbit IgG, AlexaFluor488 goat anti-rabbit and 
AlexaFluor 488 goat anti-mouse IgG antibodies were obtained from Life Technologies, UK. All other 
reagents were from previously described sources1-3. 
 
Methods 
Preparation of human Platelets  
Human blood was taken from consenting, drug-free volunteers on the day of the experiment 
according to the methodology approved by the University of Reading Research Ethics Committee. 
Blood was taken using 3.8% (w/v) sodium citrate and Acid Citrate Dextrose (ACD; 110 mmol/L 
glucose, 80 mmol/L citric acid, 120 mmol/L sodium citrate) as an anticoagulant. Whole blood was 
centrifuged at 102g for 20 minutes at 20°C to yield platelet-rich plasma (PRP). Where washed 
platelets were required, they were isolated from the PRP by further centrifugation at 1413g for 10 
minutes at 20oC in the presence of 0.1 μg/ml prostacyclin to prevent activation. The supernatant 
was discarded in Klorsept disinfectant (Medentech, Wexford, Ireland) and the platelet pellet was 
resuspended in 25ml of modified Tyrodes-HEPES buffer (134 mmol/L NaCl, 0.34 mmol/L Na2HPO4, 
2.9 mmol/L KCl, 12 mmol/L NaHCO3, 20 mmol/L HEPES, 5 mmol/L glucose, 1 mmol/L MgCl2, pH 
7.3) and 3 ml of ACD in the presence of 0.1 μg/ml prostacyclin. Platelets were centrifuged at 1413g 
for 10 minutes at 20oC and resuspended to a density of 4x108 cells/ml in modified Tyrodes-HEPES 
buffer using a platelet count obtained with a Z Series Coulter Counter (Beckman Coulter, CA, USA). 
Washed platelets were rested for at least 30 minutes at 30oC prior to the experiment to allow 
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responses to recover. Platelet preparations typically contained fewer than 1 contaminating 
erythrocyte or leukocyte per 6500 platelets. 
ADP-sensitive washed platelets were prepared by collecting blood into 3.8% (w/v) sodium citrate 
and centrifugation at 102g for 20 minutes at 20oC to yield PRP (without the addition of ACD). 
Platelets were isolated from the PRP by further centrifugation at 350g for 20 minutes. The 
supernatant was discarded, and the platelet pellet was resuspended to a density of 4x108 cells/ml 
in the modified Tyrodes-HEPES buffer. 
 
Preparation of Mouse Platelets  
Mouse blood was collected through cardiac puncture after termination by rising CO2 concentration 
and cervical dislocation as per Schedule 1 of the Animals (Scientific Procedures) Act 1986. After 
the mice were euthanized, their blood was drawn through the cardiac puncture into a syringe 
containing 4% sodium citrate (1 part sodium citrate to 9 parts blood). Red blood cells and 
leukocytes were eliminated by reducing the concentration of blood with Tyrode’s-HEPES buffer 
followed by centrifugation at 203 g for 8 minutes. The upper layer comprising PRP was gently 
aspirated with a pipette. After the addition of PGI2 (final concentration, 12.5 ng/mL) to the PRP, 
the platelets were subjected to centrifugation at 1,028 g for 5 minutes. The resulting platelet pellet 
was resuspended in modified Tyrode’s-HEPES buffer (4 × 108 cells/mL) and left to rest at 30°C for 
30 minutes. 
 
Sucrose gradient sub-cellular fractionation 
Platelet fractionation was performed as previously described with minor modifications4. Platelets 
were transferred into a cell-disruption bomb (Parr 4639, Parr Instrument Co.) and homogenized 
by nitrogen cavitation. A pressure of 1200 psi was applied with N2 to the platelet suspension and 
after 15 min the pressure was quickly released. This procedure was repeated three times and the 
final platelet homogenate was cleared from the cell debris and partially disrupted cells by 
centrifugation at 500g for 10 min. The platelet homogenate was fractionated over a linear sucrose 
gradient (from 60 to 30%, w/v in 5mM EDTA) by centrifugation at 284,061 x g for 2 hours at 4°C. 




Human blood was collected in vacutainers containing sodium citrate as described previously. The 
blood was centrifuged at 100g for 20 minutes to collect PRP. Resting or activated platelets 
(stimulated with 5 µM U46619; in the presence of 4 µM integrillin) in PRP were fixed with an equal 
volume of 8% paraformaldehyde-PBS (PFA-PBS) to make a final concentration of 4% (v/v) and 
incubated for 15 min. Thereafter, platelets were centrifuged at 950g for 10 minutes. The 
supernatant was removed, and the platelet pellet was resuspended in 2 ml of PBS-ACD (pH 6.1) 
for washing. Platelets were centrifuged for 10 minutes at 950g and resuspended in 1 ml of PBS-
ACD to concentrate platelets. Platelets were centrifuged again at the same speed for 10 minutes 
and then resuspended in 500µl of 1% (w/v) BSA-PBS, to concentrate platelets even more. Poly-L-
lysine coated-12mm coverslips (VWR micro cover glass No.1.5) were put in a 6x6 culture plate and 
90μl of platelets were added on each coverslip. Culture plates were placed at 37oC for 90 minutes. 
After 2-3 washes with PBS, samples were blocked with 0.2% (v/v) Triton-X-100, 2% (v/v) serum 
from same species as secondary antibody and 1% (w/v) protease-free BSA for 1h. Thereafter, 
primary antibodies diluted (1:100) in 0.2% (v/v) Triton-X-100, 2% (v/v) serum from the same 
species as secondary antibody and 1% (w/v) protease-free BSA were added and left overnight. The 
following day, samples were washed with PBS (2-3 times) and secondary antibodies (1:200) were 
added for 1 hour at room temperature. The unbound antibodies were washed off with PBS (2-3 
times) and samples were fixed using 4% (v/v) PFA-PBS for 5 minutes. The coverslips were washed 
again with PBS (2-3 times). Coverslips were placed on glass slides after adding ProLong Gold 
Antifade mounting media (Life technologies). The slides were kept at room temperature until 
mounting media dried and then kept in the fridge until they were imaged using a Nikon A1-R 
confocal microscope (100x oil immersion). 
 
Stochastic optical reconstruction microscopy (STORM) 
Tyrode’s-HEPES buffer was used to dilute the PRP (1:20). The polymerization of fibrin was 
prevented by treatment with GPRP (0.5 mg/mL). The samples were activated with thrombin (1 
U/mL) for 5 minutes, then the unstimulated and stimulated samples were fixed with 2% (v/v) 
formyl saline and subjected to centrifugation for 15 minutes at 500 g. After removal of the 
supernatants, the pellets containing the platelets were resuspended in Perm Buffer III (100 μL; BD 
Biosciences, Oxford, UK) and incubated on ice for 30 minutes. Platelets were then washed with 
Tyrode’s-HEPES buffer (2 × 20 minutes) and subjected to centrifugation at 500 g. The supernatant 
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was discarded, and the resultant pellet was resuspended in Tyrode’s-HEPES buffer (50 μL). The 
samples were incubated with the primary antibodies (diluted 1:50; mouse monoclonal IgG against 
integrin β3 and rabbit polyclonal IgG against Cx62) at 4 °C overnight. Platelets were then washed 
twice with Tyrode’s-HEPES buffer (2 mL) followed by centrifugation for 20 minutes at 550 g. The 
samples were incubated with secondary antibodies (diluted 1:50 in Tyrode’s-HEPES buffer; Alexa 
Fluor® 647-labeled donkey anti-rabbit to detect Cx62 and Alexa Fluor® 555-labeled goat anti-
mouse to detect β3 integrin) at 37 °C for 30 minutes. Platelets were then washed with Tyrode’s-
HEPES buffer (2 mL) and subjected to centrifugation for 20 minutes at 550 g. The resulting pellet 
was suspended in Tyrode’s-HEPES buffer (100 μL). Finally, platelets (100 μL) were applied to the 
ibidi® slides coated with poly-L-lysine. The slides were incubated at 4 °C overnight to allow the 
platelets to adhere. The next day, the unbound platelets were removed and blinking buffer was 
added (Stock A: 0.90 g/mL catalase [Sigma–Aldrich], 0.182 mM Tris [2-carboxyelthyl] phosphine 
hydrochloride [Sigma–Aldrich], 2.27% [v/v] glycerine, 1.14 mM KCl, 0.91 mM Tris-HCl [pH 7.5], 
0.045 mg/mL glucose oxidase [Sigma–Aldrich] and 5 mL diH2O; stock B: 36 mg/mL glucose, 3.6% 
[v/v] glycerine and 36 mL H2O; and stock C: 0.09 M mercaptoethylamine-HCl [Sigma–Aldrich] and 
1 mL diH2O). For 3D STORM imaging of the platelets, the 100× oil immersion lens of the microscope 
was used. 
Coordinate-based colocalization (CBC) analysis5 was performed to assess changes in the 
colocalization of Cx62 and b3 integrin upon platelet stimulation using ImageJ and the open-source 
Thunderstorm plugin.6 
 
Calcein Dye Efflux 
Platelets (in PRP) were loaded with calcein-AM (0.5 μM; Thermo Fisher Scientific, Waltham, MA, 
USA) for 30 minutes at 37 °C as described previously 7. The platelets were then treated with 
scrambled peptide or 62Gap27 for 5 minutes. Next, the platelets were stimulated with thrombin 
(0.1 U/mL). In order to prevent fibrin polymerization, the thrombin-treated samples were also 
treated with GPRP (25 μg/mL). Stimulation was carried out with gentle mixing for different time 
periods over 5 minutes. Finally, the reaction was stopped with 0.2% (v/v) formyl saline. Flow 
cytometry (488 nm excitation, 530 ± 30 nm emission) was performed with a BD Accuri™ C6 flow 
cytometer (BD Biosciences, Oxford, UK). For each sample, 10,000 events, gated on platelets by 
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forward scatter and side scatter, were collected. Data were analyzed with the built-in BD Accuri™ 
C6 Plus software (version 1.0.264.21). 
 
Fluorescence Recovery after Photobleaching (FRAP) 
FRAP analysis was performed as previously described with minor modifications8,9. Each of eight 
wells of each ibidi® slide was coated with fibrinogen (100 µg/mL) and collagen (10 µg/mL) in 
modified PBS for 1 hour. 1% (w/v) BSA was added to the wells followed by a 1-hour incubation to 
prevent the binding of platelets to the glass. The wells were washed three times with PBS. Calcein-
loaded PRP was added to the coated coverslips and incubated for 45 minutes. Unbound platelets 
were washed from the wells with PBS (three washes). The samples were then treated with the 
scrambled peptide or 62Gap27 (100 µg/mL) for 5 minutes. A high-intensity laser (488 nm) was 
trained on the central circular area (8-μm-diameter region of interest [ROI]) of the monolayer of 
cells thrombus for 300 milliseconds, resulting in an 85% loss of fluorescence. Then, a 488-nm 
wavelength laser was used to excite the samples and the fluorescence emission was detected at 
500–520 nm. Finally, fluorescence recovery was recorded for 500 seconds. The 100× oil immersion 
objective of an A1R confocal microscope was used to capture images of single sections every 
second for 500 seconds. Five thrombi from each of seven donor samples treated with scrambled 
peptide or 62Gap27 were analyzed. NIS-Elements software (Nikon, Tokyo, Japan) was used to 
compute the mean fluorescence intensities. For each time point, the average fluorescence 
intensities were computed for the background, non-bleached (reference) and bleached areas.  
 
Protein Bioinformatics 
The complete sequence of Cx62 was obtained from GenBank10, and for the physicochemical 
analysis, ProtParam11 was utilized. In the absence of an experimental structure, state-of-art 
structure prediction tools were employed to obtain 3D models for the Cx62 protomer. The 
IntFOLD4-TS method12 from the IntFOLD server13 was used to predict tertiary structure models for 
the Cx62 protomer (monomeric subunit). Additionally, the quality estimation method, 
ModFOLD614, was employed to provide both global and local (per-residue) scores for estimating 
3D model quality. The calculated local (or per-residue) errors from ModFOLD6 were mapped onto 
the model using the temperature coloring scheme ranging from blue (indicating residues modeled 
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with high quality) to red (indicating residues with lower model quality, which are often more 
flexible or disordered).  
 
Multiple sequence alignment of human connexin sequences was performed using ClustalW to 
ensure the selectivity of 62Gap27. A scrambled peptide control was designed using Mimotopes, 
(http://www.mimotopes.com/peptideLibraryScreening.asp?id=97) and BLAST searches 
performed to ensure that designed sequences were not present in any other proteins.  
To predict the most likely interactions occurring between Cx62 and the 62Gap27 inhibitor, protein-
ligand docking was performed using the SwissDock server15. The FullFitness and Gibbs free energy 
(ΔG) score of each run of the docking was evaluated and the final ranking of each cluster was based 
on the FullFitness scores.  
 
The quaternary structures of the Cx62 hemichannels (2x 6-mers) were successfully modeled using 
the PDB entry 2zw3 (crystal structure of Cx26 gap junction) as a template. The docked hemichannel 
assembly (12-mer) template for PDB ID 2zw3 was downloaded from PISA 16 service at the EBI 
(http://www.ebi.ac.uk/pdbe/prot_int/pistart.html). For each hemichannel, the template was used 
to orientate six of the modeled protomers by a six-fold symmetry axis perpendicular to the 
membrane plane and build the complete model of the docked hemichannel (12-mer) complex. 
Residues in the modeled protein-protein and protein-ligand complexes were considered to be 
interacting if the distance between the closest heavy atoms (i.e. non-hydrogen) in the residues 
belonging to different chains was <= 5Å  
 
Platelet	aggregometry	
Light transmission aggregometry (LTA) was performed in an optical platelet aggregometer 
(Chrono-Log, PA, USA, and Helena Biosciences Europe, Gateshead, UK). Washed platelets (4x108 
cells/ml) treated with 62Gap27 or scrambled peptide were stimulated in the presence of agonist 
(collagen, CRP-XL, thrombin, U46619 or ADP) with continuous stirring (1200 rpm at 37oC) for 3 
minutes and aggregation was measured as an increase in light transmittance. The data were 
quantified by considering scrambled peptide-treated samples as 100% aggregation and the level 





Fibrinogen binding and alpha granule secretion  
Fibrinogen binding and P-selectin exposure to the platelet surface were detected by flow 
cytometry as measures of integrin αllbβ3 activation and the secretion of α-granules respectively. 
Fluorescein isothiocyanate (FITC)-labelled rabbit anti-human fibrinogen antibody (Dako, Ely, UK) 
was used to measure fibrinogen binding. PE-Cy™ 5-labeled mouse anti-human CD62P antibody (BD 
Biosciences, Oxford, UK) was used to measure the exposure of P-selectin. The assay volume 
comprising human or mouse PRP, an inhibitor of Cx function or appropriate scrambled peptide 
control and each of the antibodies in modified Tyrode’s-HEPES buffer, was incubated for 5 minutes 
at room temperature in the dark. The platelet agonists thrombin (in the presence of GPRP to 
prevent fibrin polymerization) or CRP-XL were added and incubated for an additional 20 minutes. 
The reaction was stopped by the addition of 0.2% (v/v) formyl saline. A BD Accuri™ C6 flow 
cytometer (BD Biosciences, Oxford, UK) and BD Accuri™ C6 software were used for the acquisition 
of the flow cytometry data. The median fluorescence intensity was calculated for 10,000 gated 
events. Fluorescence in FL1-A and FL3-A channels were used to analyze fibrinogen binding and P-
selectin exposure, respectively. 
 
Dense	granule	secretion	
Dense granule secretion was determined by measuring changes in the extracellular ATP 
concentration. These changes were observed concurrently with aggregation in a Model 700 Whole 
Blood/Optical Lumi-Aggregometer with the use of a luciferase kit (Chrono-Log, Havertown, PA, 
USA). ATP release from dense granules was monitored with a bioluminescence system comprising 
D-luciferin, firefly luciferase and magnesium. ATP interactions with these reagents produce light, 
in direct proportion to the ATP concentration, which is observed and quantified using a Lumi-
aggregometer. Platelets (4 × 108 cells/mL) were pre-treated with 62Gap27 or scrambled peptide at 
37°C for 5 minutes. Luciferase was added under stirring conditions during the last 2 minutes of the 
incubation. The platelets were stimulated with the indicated concentrations of thrombin or CRP-
XL under stirring conditions (1,200 rpm at 37°C). ATP release and aggregation at 37°C were 
recorded for 3 minutes following the addition of agonist using the AggroLink8 software, which 





The TxB2 measurements were performed with a TxB2 immunoassay kit based on a competitive 
ELISA (Cayman Chemical, Cambridge, UK), according to the manufacturer’s instructions. Washed 
platelets (4 × 108 cell/mL) were treated with 62Gap27 or scrambled peptide for 5 minutes in glass 
cuvettes. The samples were then activated with CRP-XL or thrombin. After 5 minutes, stop solution 
(1 mM EGTA and 10 μM indomethacin) was added to terminate the reaction. The samples were 
then immediately subjected to centrifugation for 2 minutes at 12,000 rpm and the supernatants 
were frozen at −80°C. Later, the supernatants were thawed and diluted 1:40 in ELISA buffer (0.01% 
[w/v] sodium azide, 1 mM EDTA, 400 mM NaCl, 0.1% [w/v] BSA and 100 mM phosphate). The 
dilutions were plated in wells coated with polyclonal goat anti-mouse IgG antibodies. To determine 
the relationship between the TxB2 concentration and absorbance, TxB2 standards were prepared. 
TxB2-acetylcholinesterase and anti-TxB2 monoclonal antibody were added to each well, then the 
plate was incubated at room temperature for 2 hours. After incubation, the plate was washed 4 
times with washing buffer. Next, Ellman’s reagent was added to each well and the plate was 
incubated in the dark. A NOVOstar plate reader (BMG Labtech, Aylesbury, UK) was used to 
determine the absorbances of the wells at 405 nm. A standard curve was plotted using the 
absorbance readings for the TxB2 standards. The inverse function was used to compute the TxB2 
concentrations from the test sample readings. 
	
Measurement	of	intracellular	calcium	mobilization	
The mobilization of Ca2+ from intracellular stores into the platelet cytosol was measured in a 
fluorescence-based 96-well plate assay. PRP was incubated with 2 μM Fura-2 AM for 60 minutes 
at 30°C. The PRP was washed and subjected to centrifugation at 350 g for 20 minutes, then 
resuspended in modified Tyrode’s-HEPES buffer containing	CaCl2	(1mM) at 4 × 108 cell/mL. Fura-
2-loaded platelets were incubated with 62Gap27 or scrambled peptide for 5 minutes at 37°C, then 
stimulated with the agonists, CRP-XL or thrombin. A NOVOstar plate reader (BMG Labtech, 
Aylesbury, UK) was used to measure the fluorescence (excitation at 340 and 380 nm and emission 
at 510 nm). The ratio of the excitation signals at 340 and 380 nm was used to estimate the 




The cells were lysed with digitonin (5 μM) to release the Fura-2 into the assay buffer (which 
contained 1 mM CaCl2) and facilitate the measurement of the maximum fluorescence ratio. The 
minimum fluorescence ratio was measured by chelating Ca2+ ions with EGTA (10 mM) and Tris base 
(10 mM; added to ensure that the pH remained alkaline for optimum Ca2+ buffering by EGTA). Non-
Fura-2-loaded cells at the same final density were used to measure the autofluorescence levels. 
Using the calibration values from above, experimental [Ca2+]i concentrations were calculated using 
the following equation:  







Where Kd is the dissociation constant of Fura-2AM (~224 nM). Sf and Sb are the values of the 
fluorescence at 380nm excitation (corrected to background auto-fluorescence), with zero or 
saturating [Ca]2+ respectively. R is the 340/380nm fluorescence ratio, corrected for background 
fluorescence. Rmin and Rmax are the ratio limits at zero or saturating [Ca]2+, respectively, adjusted 
using a viscosity constant of 0.85. This corrects for the effects of the cellular environment on the 
fluorescence of Fura-2. 
 
Platelet adhesion and spreading 
To study platelet spreading, glass coverslips coated with fibrinogen (100 μg/mL in modified PBS) 
were placed in 6-well plates. After coating for 1 hour, 1% (w/v) BSA was added to the coverslips 
followed by 60 minutes incubation to prevent platelets from binding the glass. The coverslips were 
then washed three times with PBS. The washed platelet suspensions (2 × 107 cells/mL) that had 
been incubated for 5 minutes with 62Gap27 or scrambled peptide were then added to the 
coverslips and incubated at 37°C for 45 minutes. Unbound platelets were removed, and the 
coverslips were washed three times with PBS. Then, the coverslips were fixed in 0.2% (v/v) formyl 
saline for 10 minutes. The coverslips were again washed three times with PBS. Next, the platelets 
were permeabilized with 0.2% (v/v) Triton™ X-100 for 5 minutes, then washed three times with 
PBS. The coverslips were incubated with Alexa Fluor® 488-conjugated phalloidin for 1 hour in the 
dark to label filamentous actin. The supernatants were removed, the coverslips were washed with 
PBS and placed on glass slides and fluorescence was preserved by adding ProLong™ Gold Antifade 
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Mountant. The 100× oil immersion lens of the Nikon A1R confocal microscope (Nikon, Tokyo, 
Japan) was used to image samples (excitation at 488 nm from an argon laser, emission between 
500 and 520 nm). Images were taken in a single focal plane. In order to determine platelet 
adhesion, the numbers of platelets in five random images of each coverslip were counted. Platelets 
were categorized as spread fully (lamellipodia formed), partially spread (defined as filopodia) or 
adhered (not spreading). Finally, the relative frequencies of these groups were computed. 
 
Clot retraction 
Human PRP was prepared and rested at 30°C for 30 minutes. Red blood cells and 62Gap27 or 
scrambled peptide were mixed with the PRP. The mixture was adjusted to a final volume of 1 mL 
with modified Tyrode’s-HEPES buffer and incubated for 5 minutes at room temperature. Thrombin 
(final concentration, 1 U/mL) was added to initiate clot generation. A glass pipette was added to 
the center of each test tube, around which the clot would form, and samples were placed in an 
incubator chamber at 37oC. Photographs were taken every 10 minutes and the assay was 
terminated after 60 minutes at which time the clot in the scrambled peptide-treated samples was 
seen to have retracted completely. Clot weight was measured as a marker for clot retraction. Clots 
were removed from the glass pipettes and transferred into the pre-weighed microfuge tubes. Clot 
mass was determined by subtracting the weight of pre-weighed microfuge tubes from the weight 
of microfuge tubes containing clot.  
 
In vitro thrombus formation under flow 
Whole human blood was incubated with the lipophilic dye DiOC6 (5 µM) at 30 °C for 1 hour. Vena8 
BioChip microfluidic channels were coated with type I collagen (100 μg/mL) for 1 hour. Channels 
were washed with modified Tyrode’s-HEPES buffer to remove excess collagen. Whole blood was 
incubated with 62Gap27 or scrambled peptide for 5 minutes. Then, the blood samples were 
perfused through the collagen-coated channels at an arteriolar shear rate of 20 dyne/cm2. An 
argon laser was used to excite fluorescence (488 nm) and emission was recorded at 500–520 nm. 
Thrombus formation on the microfluidic chip was observed through the 20x objective of the Nikon 
A1R confocal microscope. Images of single sections were obtained every second for 600 seconds. 




In vivo thrombus formation 
C57BL/6 mice were anaesthetised with intraperitoneally administered atropine (0.25 mg/kg), 
xylazine (12.5 mg/kg) and ketamine (125 mg/kg). When needed, pentobarbital (5 mg/kg) was used 
to sustain anesthesia. After the exteriorization of the cremaster muscle and removal of the 
connective tissue, an incision was made in the muscle, resulting in its adherence as a single layer 
to the glass slide. A buffer (135 mM NaCl, 4.7 mM KCl, 2.7 mM CaCl2 and 18 mM NaHCO3; pH 7.4) 
was used to hydrate the muscle. 
Before the injury (made with a MicroPoint Ablation Laser Unit; Andor Technology, Belfast, UK), 
62Gap27 or scrambled peptide and DyLight® 649-conjugated anti-GPIbα antibody (to label 
platelets; 0.2 μg/g mouse weight), were introduced into the circulation through a cannula in the 
carotid artery. After 5 minutes of administration of 62Gap27 or scrambled peptide, the formation 
of thrombi was observed with an Olympus BX61W1 microscope (Olympus, Tokyo, Japan). A 
Hamamatsu digital camera (C9300; Hamamatsu Photonics, Welwyn Garden City, UK) with charge-
coupled device camera in 640×480 format was used to obtain images before and after injury. The 
images were analyzed with SlideBook 6 software (Intelligent Imaging Innovations, Denver, CO, 
USA). The protocol from the Home Office license was followed for the sacrifice of the mice. The 
protocol was also approved by the Animal Welfare and Ethics Research Board and the University 
of Reading local ethics review panel. 
 
Tail Bleeding Assay  
C57BL/6 mice were anesthetized by intraperitoneal administration of xylazine (12.5 mg/kg) and 
ketamine (125 mg/kg). 62Gap27 or scrambled peptide was administered through injection via the 
femoral vein. After 5 minutes of infusion, the tips of the tails (0.3 cm) were cut with a scalpel and 
immediately placed in tubes with saline in a manner that prevented the cut ends of the tails from 
touching the walls of the tubes. The bleeding time was recorded until blood flow stopped or for 
up to 20 minutes. The mice were sacrificed according to the protocol that was approved by the 
University of Reading local ethics review panel, the Animal Welfare and Ethics Research Board and 





cAMP ELISA  
A cAMP immunoassay kit based on a competitive ELISA (Cell Signaling Technology, Hitchin, UK) 
was used to assess cAMP levels, according to the protocol provided by the manufacturer. Washed 
platelets (4 × 108 cell/mL) were added to a glass cuvette and treated with 62Gap27 or scrambled 
peptide for 5 minutes. After 5 minutes of stimulation with CRP-XL or thrombin, lysis buffer (Triton™ 
X-100: 1% polyethylene glycol octylphenol ether) was added to the samples. The samples were 
immediately frozen at −20°C. The samples were later thawed and added to microwells coated with 
cAMP XP® rabbit monoclonal antibody. The association between cAMP concentration and 
absorbance was determined using cAMP standards. The assay plate was covered and incubated 
on a horizontal orbital plate shaker for 3 hours at room temperature. After incubation, the 
contents of the wells were removed and the wells were washed with 1x washing buffer three 
times. Then, 3,3',5,5'-tetramethylbenzidine substrate was added to the wells and the plate was 
incubated for 30 minutes. Stop solution was added to terminate the reaction. The absorbance at 
450 nm was periodically determined with a NOVOstar plate reader (BMG Labtech, Aylesbury, UK). 
A standard curve was plotted from the absorbance readings of the cAMP standards. cAMP 
concentrations were computed for the test sample readings via the inverse function. 
 
Western blotting 
To study cell signaling, human or mouse washed platelets were prepared at a density of 4x108 
cells/ml under non-aggregation conditions [indomethacin (20 µM), cangrelor (1 µM), MRS2179 
(100 µM) and EGTA (1 mM). These platelets were treated with an inhibitor of Cx function or 
scrambled peptide control for 5 minutes and then stimulated with platelet agonists in the 
aggregometer. Unstimulated or stimulated samples were lysed with 6X Laemmli sample reducing 
buffer and heated to 95oC for 5 minutes before storing at -20oC until use. 
The proteins in the extracts of the platelet lysates were separated by SDS-polyacrylamide gel 
electrophoresis (PAGE) after heating to 95°C for 10 minutes in 6x Laemmli reducing buffer. The 
samples and molecular weight standards were loaded onto 4%–20% acrylamide gradient gels (Bio-
Rad precast gels; Bio-Rad, Watford, UK). The gels were run at a constant voltage (100 V) for 90 
minutes in a Mini-PROTEAN® II apparatus (Bio-Rad, Watford, UK) with Tris-glycine buffer in the 
 50 
running reservoir. The separated proteins were transferred to PVDF membranes (Bio-Rad, 
Watford, UK) by semi-dry transfer. PVDF membranes, soaked in methanol, were placed under the 
resolving gels. Four sheets of 3-mm filter paper soaked in anode buffer (300 mM Tris base and 20% 
[v/v] methanol; pH 10.4) were placed below the membranes and 4 sheets of 3-mm filter paper 
soaked in cathode buffer (25 mM Tris base and 40 mM 6-amino-n-hexanoic acid; pH 9.4) were 
placed above the resolving gels. The proteins were transferred from the gels to the membranes by 
applying a constant voltage (15V) for 2 hours.  
The PVDF membranes were blocked with 5% (w/v) BSA dissolved in 1% (v/v) Tris-buffered saline–
TWEEN® 20 for 1 hour at room temperature. The membranes were incubated with the primary 
antibodies, which were diluted in 1% (v/v) TBST with 2% (w/v) BSA, overnight at 4°C. After 
overnight incubation, the membranes were washed with TBST (3 × 5 minutes) to remove unbound 
antibodies. Fluorescently labeled secondary antibodies diluted in 1% (v/v) TBST containing 2% 
(w/v) BSA were then applied to the membranes, which were incubated for 1 hour at room 
temperature in the dark. The membranes were then washed with TBST (3 × 5 minutes) and their 
fluorescence visualized using a Typhoon FLA 9500 fluroimager (Amersham Biosciences, 
Buckinghamshire, UK). Image Quant software version 8.1 (GE Healthcare) was used to quantify the 















Supplemental Figure 1 
 
Supplemental Figure 1. Localization of Cx62 in platelets. (A) Treatment	 of	 platelets	with	 secondary	
antibody	 alone	 (in	 the	 absence	 of anti-GJA10	 primary	 antibody)	 was	 performed	 during	 STORM	
microscopy	 to	 exclude	 the	 possibility	 of	 non-specific	 staining	 (B) Cx62 is distributed in low-density 
subcellular platelet fractions. Ultracentrifugation was utilized to separate platelet homogenates on a 
sucrose density gradient. The fractions were separated by SDS-PAGE and immunoblotted for Cx62, β3 
integrin, calreticulin, RabGDIb and TSP-1. The lower-density platelet fractions (lanes 1–6) are identified by 
the DTS protein calreticulin, surface marker integrin β3, and the cytosolic marker RabGDIb. The α-granule 
protein TSP-1 was used to identify the heavier fractions. A Typhoon™ FLA 9500 fluorimager was utilized to 
examine the immunoblots (GE Healthcare, UK). The results are representative of 3 individual experiments.  
WPL: whole platelet lysate. (C) Effects of 62Gap27 (100 μg/ml) on thrombin (0.1 U/ml) mediated P-selectin 
exposure, in comparison to the scrambled peptide (S; 100 μg/ml) was evaluated using flow cytometry. (D) 
Structural representation of the target region to which the 62Gap27 mimetic peptide was designed, and the 






Supplemental Figure 2 
 
Supplemental Figure 2. 62Gap27 inhibits platelet aggregation and fibrinogen binding to integrin αIIbβ3. (A) 
Washed human platelets (4×108 cells/mL) were treated with vehicle (V; ddH2O) or scrambled peptide (S; 100 
μg/ml) and stimulated with CRP-XL or thrombin. Aggregation was measured using optical light transmission 
aggregometry for 180 seconds. Representative aggregation traces are shown (B, C) Washed human platelets 
(4×108 cells/mL) were treated with 62Gap27 or scrambled peptide (100 μg/ml) for 5 minutes prior to their 
stimulation with (B) U46619 (EC50: 0.25–0.4 μM) or (C) ADP (EC50: 5–10 μM). Aggregation was measured optical 
light transmission aggregometry for 180 seconds. Representative aggregation traces and quantified data shown 
(Scrambled-treated samples represent 100% aggregation) (D) Effects of the vehicle (V; ddH2O) and scrambled 
peptide (S; 100 μg/ml) on CRP-XL (0.25 µg/ml) and thrombin (0.05 U/ml) mediated fibrinogen binding was 
evaluated in platelets (in PRP) using flow cytometry. Data represent mean ± SEM (n≥3), **P˂0.01, ***P˂0.001 









Supplemental Figure 3 
 
Supplemental Figure 3. Characterization of Cx57-/- platelets. Cx57+/+ and Cx57−/− platelets were used to 
evaluate the expression of (A) Cx37 and (B) Cx40 by immunoblotting.  (C) Cx37+/+, Cx37−/− and (D) Cx40+/+, 
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Cx40−/− platelets were used to analyze the expression of Cx57 by immunoblotting. Actin was used as a 
loading control. Quantified data shown. The	expression	levels	of	(E)	GPVI	(F)	α2β1,	(G)	αIIbβ3	and	
(H)	GPIb	were	analyzed	in	resting	and	CRP-XL-activated	(1	μg/ml)	platelets	from	Cx57+/+	and	Cx57-
/-	mice	by	flow	cytometry. The student t-test was used for statistical analysis. 
Supplemental Figure	4	
	
Supplemental Figure 4. Cx57 functions independently of Cx37 and Cx40 in platelets. PRP from (A) Cx37+/+ and 
Cx37-/- and (B) Cx40+/+ and Cx40-/- mice was treated with 62Gap27 (100 µg/ml) or scrambled peptide (S; 100 μg/ml) 
for 5 minutes. Fibrinogen binding levels were evaluated after stimulation with CRP-XL (1 µg/ml). (C) Effects of 
scrambled peptide (S; 100 μg/ml) and vehicle (V: ddH20) on CRP-XL (0.25 µg/ml) and thrombin (0.05 U/ml) 
mediated P-selectin exposure was evaluated in platelets (in PRP) using flow cytometry. (D) DiOC6-loaded human 
whole blood was treated with scrambled peptide or 62Gap27 (100 μg/ml) for 5 min before perfusion through 
collagen-coated (100 μg/mL) Vena8Biochips at a shear rate of 500 s-1 (20 dyne/cm2). Quantified	data	display	
surface	coverage	of	 thrombus	over	a	period	of	10	minutes. Data represent mean ± SEM (n≥3). *P˂0.05 and	











Supplemental Figure 5. 62Gap27	 inhibits	 thrombin-mediated	 signaling	 in	 human	 platelets. (A) 1 
Fura-2AM-loaded washed platelets (4×108 cells/mL)	were incubated with 62Gap27 (50 or 100 μg/mL) or 2 
scrambled peptide (S, 100 μg/mL) for 5 minutes in the presence of EGTA and stimulated with CRP-XL (0.5 3 
μg/mL) for 5 minutes. Spectrofluorimetry was used to measure the release of calcium from intracellular 4 
stores. Representative traces of calcium mobilization over a period of 5 minutes and quantified data (peak 5 
calcium levels) are shown.	(B) Representative blot and quantified data indicate the levels of phosphorylated 6 
total tyrosine in washed human platelets (4×108 cells/mL). Resting human platelets (R) were pre-incubated 7 
with scrambled peptide (S) or 62Gap27 (100 μg/mL) for 5 min then were stimulated with thrombin (T; 0.05 8 
U/ml). (C) Calcium mobilization and (D) release of calcium from intracellular stores was measured in Fura-9 
2AM-loaded washed platelets (4×108 cells/mL)	treated with scrambled peptide (S; 100 μg/mL) or 62Gap27 10 
and stimulated with thrombin (0.05 U/ml). Representative traces of calcium mobilization over a period of 11 
5 minutes and quantified data (peak calcium levels) are shown. (E) Representative blot and quantified data 12 
indicate the levels of phosphorylated PKC substrate in washed human platelets (4×108 cells/mL). Resting 13 
human platelets (R) were pre-incubated with scrambled peptide (S) or 62Gap27 (100 μg/mL) for 5 min then 14 
were stimulated with thrombin (T; 0.05 U/ml). (F) Representative blot and quantified data indicate the 15 
levels of pERK1/2 in washed human platelets (4×108 cells/mL). Resting human platelets (R) were pre-16 
incubated for 5 minutes with Scrambled peptide (S) or 37,43Gap27 or 62Gap27 (100 μg/mL) and stimulated 17 
with thrombin (T; 0.05 U/ml) or CRP-XL (C; 1	μg/ml). Actin was used as a loading control. Data represent 18 
the mean ± SEM (n≥3). *P˂0.05,	**P˂0.01,	****P˂0.0001	and	####P<0.0001 was	calculated	by	one-way	19 















Supplemental Figure 6 1 
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Supplemental Figure 6. 62Gap27 modulates PKA activity. (A) Resting washed human platelets 3 
(4×108 cells/mL) treated with scrambled peptide (S; 100 μg/mL) or 62Gap27 (50 and 100 μg/mL) for 5 4 
minutes were tested for VASP S239 phosphorylation (a marker of PKG activity). Platelets treated with PAPA-5 
Nonoate (NO; 100 μM) for the stimulation of PKG-mediated phosphorylation were used as positive 6 
controls. (C) Resting washed human platelets (4×108 cells/mL) treated with scrambled peptide (S) or 7 
37,43Gap27 or 62Gap27 (100 μg/mL) for 5 minutes were tested for VASP S157 phosphorylation. Platelets 8 
treated with PGI2 (1 μg/mL) were used as a positive control. (D) Resting washed human platelets 9 
(4×108 cells/mL) were treated with GF109203X (10 µM), (E) LY29400 (100 µM) or (F) AKT inhibitor IV (5 µM) 10 
for 5 minutes before incubation with the scrambled peptide or 62Gap27 (100 μg/mL) for 5 minutes. Samples 11 
were assayed for VASP-S157 phosphorylation. 14-3-3-ζ was detected by immunoblotting as a loading 12 
control. Representative blots are shown. Data represent the mean ± SEM (n≥3). *P˂0.05 was calculated by 13 
one-way. 14 
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